Dr. Alberto Mendivil, M.D.
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Utah School of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 196
Licensed in California since 2005, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Utah School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
CA license A90983 (first issued 2005; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hoag Memorial Hospital Presbyterian Newport Beach, CA
- Providence Mission Hospital Mission Viejo, CA
- Providence St. Jude Medical Center Fullerton, CA
Medical groups
- Hoag Clinic (460 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 196
- Services billed
- 767
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 211 | 115 |
| Established patient office or other outpatient visit, 20-29 minutes | 73 | 64 |
| Established patient office or other outpatient visit, 40-54 minutes | 52 | 29 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 43 | 17 |
| New patient office or other outpatient visit, 60-74 minutes | 35 | 35 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 30 | 30 |
| New patient office or other outpatient visit, 45-59 minutes | 27 | 27 |
| Imaging of lymph nodes during surgery | 18 | 18 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 15 | 14 |
| Biopsy of lining of uterus | 13 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Newport Beach, CA | 28 |
| Prochlorperazine Maleate Other prescribers in Newport Beach, CA | 22 |
| Eliquis (apixaban) Other prescribers in Newport Beach, CA | 21 |
| Estradiol Other prescribers in Newport Beach, CA | 14 |
| Duloxetine Hcl Other prescribers in Newport Beach, CA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 8 payments worth $5,319 in total to this clinician.
| AbbVie Inc. | $5,302 |
|---|---|
| GlaxoSmithKline, LLC. | $17.49 |
| Consulting Fee | $4,550 |
|---|---|
| Travel and Lodging | $658 |
| Food and Beverage | $111 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Oct 20, 2025 | Consulting Fee ELAHERE · ONCOLOGY | $2,800 |
| AbbVie Inc. Oct 20, 2025 | Consulting Fee ELAHERE · ONCOLOGY | $1,750 |
| AbbVie Inc. Sep 12, 2025 | Travel and Lodging ELAHERE · ONCOLOGY · travel to DENVER, CO · in-kind | $628 |
| AbbVie Inc. Oct 20, 2025 | Travel and Lodging ELAHERE · ONCOLOGY · travel to SANTA ANA, CA · in-kind | $30.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $198,013 in research payments for these studies, mostly to the institutions running them.
- Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
AbbVie Inc. · Active, not recruiting · NCT05456685 - A phase 3, randomized, double-blind, multicenter study of dostarlimab
GlaxoSmithKline, LLC. - A randomized, double-blind, phase 3 comparison of platinum-based thera
GlaxoSmithKline, LLC. - A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer KEYNOTE-A18 , ENGOT-cx11,GOG-3047
Merck Sharp & Dohme LLC - A phase 1 dose escalation and cohort expansion study of TSR-042, an an
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.